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Cognitive impairment (CI) is increasingly recognized as a common adverse consequence of heart failure (HF). Although the exact
mechanisms remain unclear, microembolism, chronic or intermittent cerebral hypoperfusion, and/or impaired cerebral vessel
reactivity that lead to cerebral hypoxia and ischemic brain damage seem to underlie the development of CI in HF. Cognitive
decline in HF is characterized by deﬁcits in one or more cognition domains, including attention, memory, executive function,
and psychomotor speed. These deﬁcits may aﬀect patients’ decision-making capacity and interfere with their ability to comply
with treatment requirements, recognize and self-manage disease worsening symptoms. CI may have ﬂuctuations in severity over
time, improve with eﬀective HF treatment or progress to dementia. CI is independently associated with disability, mortality, and
decreased quality of life of HF patients. It is essential therefore for health professionals in their routine evaluations of HF patients
to become familiar with assessment of cognitive performance using standardized screening instruments. Future studies should
focus on elucidating the mechanisms that underlie CI in HF and establishing preventive strategies and treatment approaches.
1.Introduction
Heart failure (HF) is a major and growing health problem
in the developed world that aﬀects 1-2% of the adult
population and 6–10% of people over the age of 65 [1, 2].
HF is associated with frequent hospital admissions, reduced
quality of life, signiﬁcant morbidity, and increased mortality
[3–6]. It is estimated that elderly HF patients have high read-
mission rates ranging from 40 to 50% within 6 months [7].
Signiﬁcant predictors of HF decompensation and high read-
missionratesincludepatients’poorcompliancewiththerapy
and diet restrictions, and their failure to recognize early
symptoms of HF deterioration which may be the conse-
quences of cognitive impairment (CI) and poor insight [8].
S e v e r a ls t u d i e sh a v ed e m o n s t r a t e dt h a tC Ii sp a r t i c u l a r l y
common in HF with 30% to 80% of patients with HF expe-
riencing some degree of cognitive impairment [9, 10]. This
wide range in CI prevalence estimates is believed to be the
result of diverse study designs, HF severity, age of patients,
sample sizes, neuropsychological tests, and diagnostic
criteria between diﬀerent studies. HF adversely aﬀects var-
ious aspects of cognitive functioning, including attention,
learning ability and delay recall, working memory, executive
function, and psychomotor speed [9–11]. Areas of cognition
less aﬀected are the language domain and possibly visu-
ospatial functions although both domains have not been
adequately investigated in patients with HF [12]. Most of the
patientswithHFandCIsuﬀerfrommildimpairmentincog-
nition whereas about 25% may have moderate-to-severe CI
[9]. In addition, HF severity has been linked to increased
risk of CI [13], while eﬀective treatment of HF, use of ACE
inhibitors, and physical activity lead to improvement in
cognitive performance [14] which imply that CI may ﬂuc-
tuate in severity and can also be modiﬁed to some degree.
In this paper, we outline the spectrum of cognitive func-
tionaldomainsanddescribethespeciﬁcpatternsofcognitive
decline and their consequences in patients with HF. We
also discuss the current understanding of the underlying
mechanisms that aﬀect neuronal function in HF and ﬁnally
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2. Cognitionand CognitiveImpairment
Cognition is a collective term for higher cortical functions
suchasthinking,remembering,knowing,planning,andana-
lyzing. Cognition is crucial for a person to become aware of
his/her situation, needs, and goals and meet the challenges
of daily life [15]. Cognitive functioning encompasses various
speciﬁc aspects referred to as cognitive domains that include
memory, attention, executive functioning, psychomotor
speed, language, and visuospatial ability. Positron emission
tomography and functional MRI have shown that each cog-
nitive domain involves diverse and often overlapping parts of
the brain.
Severalmeasuresofcognitivefunctioningareavailable.A
measure of global cognition that is often used by the clini-
cians as a screening instrument is the Mini-Mental State
Examination (MMSE). MMSE is a 30-point test that pro-
vides information about orientation, working and episodic
memory, attention, calculation, naming, copying, language
comprehension, and visuospacial construction. Very often,
however, a more detailed neuropsychological assessment is
required. For this purpose, a number of neuropsychological
tests are available, designed for the assessment of diﬀerent
cognitive domains and the calculation of cognitive dysfunc-
tion severity.
CI is a broad term that generally describes a decline in
cognitive functions. The severity of this impairment may
range from mild symptoms to severe cognitive deﬁcits that
may warrant the diagnosis of dementia. Mild cognitive
impairment is described as a transition phase between nor-
mal ageing and dementia. This syndrome reﬂects the clinical
situationinwhichapersonhassubjectivecomplaintsofCIas
well as objective measurements of cognitive decline (around
1.5 standard deviations below normative data) along with
intact daily functioning [16]. Mild cognitive impairment
may involve single or multiple domain deﬁcits (with or with-
out memory impairment). Individuals with mild cognitive
impairment are in increased risk of progression to dementia
[17]. Dementia is characterized by progressive impairment
in more than one cognitive domain. Routine laboratory tests
for dementia include measurement of liver, renal and thyroid
function, vitamin B12 levels, and imaging of the brain (CT
or MRI). After excluding reversible causes, four common
dementia syndromes, that is, Alzheimer’s disease, vascular
dementia, dementia with Lewy body, and frontotemporal
dementia, account for 90% of all cases. These dementias
have distinct clinical features, cognitive proﬁles, and imaging
abnormalities [18].
3.Pathophysiology ofCIinHF
The exact pathophysiologic mechanisms that underlie the
development of CI in a proportion of patients with HF
continue to be investigated and much research is conducted
in the ﬁeld. Studies have provided evidence that the clinically
detected CI in patients with HF can be the outcome of
structural or neurodegenerative changes which cannot be
reversed and/or functional neuronal dysfunction which may
progress to neuronal cell death or improve in response to
treatment.
Cerebral and systemic hemodynamics seem to inﬂuence
the development of CI in patients with HF. Cerebral blood
ﬂow (CBF), estimated with single-photon emission com-
puted tomography (SPECT), was reduced about 30% in
patients with severe HF (NYHA class III/IV) [19]. In another
study the degree of CI in HF was related to regional CBF
reductions particularly in the posterior cortical areas of the
brain [20]. Interestingly, CBF in patients with severe HF was
restored after heart transplantation [19]. These data suggest
that cognitive performance in patients with HF appears to be
closely related to the measurements of cerebral perfusion.
Cerebral perfusion is mediated by a number of factors
including cardiac output and cerebrovascular reactivity. Low
systolic blood pressure was shown to be an independent
predictor of CI in HF patients [21]. In addition, low card-
iac output was associated with impairment in cognitive per-
formance [22–26] and dementia [27]. Furthermore, cere-
brovascular reactivity, measured as the response to cerebral
vasodilatory eﬀects of carbon dioxide, was found to be
impaired in patients with HF and correlated with left ven-
tricular ejection fraction and NYHA class [28]. It appears
thereforethatlowcardiacoutput,lowsystolicbloodpressure,
andimpairedcerebralneurohormonalautoregulatorymech-
anisms in HF result in a decrease in cerebral blood ﬂow that
may account for the neuroanatomic and neuropsychological
changes [29].
Another aspect of the pathophysiology of CI in HF is the
development of cerebral abnormalities as a result of chronic
hypoperfusion or stroke [30–33]. Cardiac output was shown
to be associated with lower brain volumes and information
speed processing [24]. In addition, some brain regions
including the frontal cortex and parahippocampal gyrus,
which are considerably implicated in cognition, seem to be
more vulnerable in patients with HF [34]. MRI studies have
alsorevealed[35]thatHFpatientshaveincreasedfrequencies
of focal brain abnormalities ranging from multiple cortical
orsubcorticalinfarctstosmallvesseldiseasewithwhite-mat-
ter lesions and lacunar infarcts with cerebral embolism and
hypoperfusion being the most plausible mechanisms [36].
ThelocationofthelesionsineachindividualwithHFislikely
to determine the domain speciﬁc impairment and these dif-
ferences among patients with HF may account for the incon-
sistencies between the studies regarding the impairment of
speciﬁc domains. In addition to location, lesion load and
the ensuing cortical atrophy are also important determinants
of cognitive impairment. Imaging techniques that integrate
lesion location and burden would be valuable tools in pre-
dicting the cognitive consequences of HF.
4. Impairment of CognitiveDomains in
Heart Failure
In most studies investigating the association between HF
andcognitiveperformanceusingvariousneuropsychological
tests, the term CI was used without specifying if the criteria
formildCIorspeciﬁcdementiasineachindividualweremet.
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domain, were searched by comparing the test scores between
patients and controls or normative data [9, 11, 12, 37]. This
approach may account for the inconsistencies between the
studies regarding the prevalence of CI and the impaired
domains. In the following section we brieﬂy describe the
main cognitive domains and the identiﬁed CI proﬁles in HF
patients.
4.1. Memory. Memory is a basic cognitive function, which
includes three main stages: registration, storage, and retriev-
al. Several types of memory exist, each involving diﬀerent
brain areas. The most important types for clinical use are
the episodic memory which refers to the memory of speci-
ﬁc personal events and experiences and the semantic mem-
ory which reﬂects the memory of meanings and general
knowledge. Memory involves structures mainly within the
medial temporal lobe, such as the hippocampal region,
the entorhinal, perirhinal, and parahippocampal cortex
[38]. Other regions related to memory include diencephalic
nuclei,themammillarybodies,portionsofthethalamus,and
prefrontal areas. Memory loss is a usual complaint of many
elderly people. Interview questions regarding the patient’s
personal life and public events are useful for an initial screen
of memory problems. The California Verbal Learning Test
(CVLT) and the Rey Auditory Verbal Learning Test (AVLT)
are memory tests that require learning and immediate recall
(immediate memory) of lists of words repeatedly presented.
Then a second list of words is presented. After some time
has elapsed the patient is asked to recall the ﬁrst list (delay
memory)[39].Episodicmemoryimpairment,whichisman-
ifested as impaired ability to acquire, encode, and retrieve
new information, is the main cognitive deﬁcit in Alzheimer’s
diseaseandisdirectlyrelatedtomesialtemporallobeatrophy
[40]. Semantic memory is assessed through category ﬂuency
tests, picture-naming tests and word-picture matching tests.
Deﬁcits in semantic memory may be present in Alzheimer’s
disease or more prominently in semantic dementia [41]. In
HF several studies have revealed cognitive deﬁcits in both the
initial learning of information and the delay recall of that
information at a later time point [11, 13, 42–53]. However,
some other studies did not conﬁrm a decline in initial learn-
ing scores [54–56].
4.2. Attention-Working Memory-Psychomotor Speed. Atten-
tion is the ability to concentrate and focus selectively on a
stimulus without being distracted by the background noise.
Intact attention is essential for the patient’s performance
in other cognitive tasks. Working memory is a function of
attention important for information processing. It refers to
the ability to maintain and manipulate information tempo-
rarily in the mind and then retrieve it accurately in a few
seconds, for instance, our ability to remember a phone num-
ber within a period of 30 seconds. The prefrontal cortex is
considered the major brain structure involved in working
memory. However, various other brain areas including par-
ietal cortex, subcortical, and cerebellar regions also partici-
pate in working memory [57]. Serial subtractions of 7
from 100 are an easy and frequently used test for detecting
attention problems. Attention and working memory can also
be assessed using the digit span forwards and backwards
and the Trail-Making-Test-A (TMT-A) in which individuals
are instructed to connect sequential numbers by drawing
lines. Impairment of attention and working memory is a fea-
ture of various medical conditions, including delirium and
dementia.Anotherimportantaspectofcognitionisthespeed
of information processing or else the psychomotor speed. It
refers to the reaction time between a stimulus and the sub-
sequent response. It represents a basic cognitive domain that
aﬀects other domains, especially executive functions. Proces-
sing speed is globally distributed in the brain and is depen-
dent on the connectivity of nearly all cortical regions. It is
believed that subcortical areas play an important role in this
cognitive process [58]. Psychomotor slowing is characteristic
of vascular, subcortical, and multi-infarct dementia [59, 60].
TheDigitSymbolSubstitutionTest(DSST)isausefultestfor
the assessment of psychomotor speed. This test consists of 9
digit-symbol pairs. The patient is given an array of digits and
is required to write the corresponding symbol beneath each
digit as fast as possible. Another test used for the assessment
of processing speed is the TMT-A and TMT-B. TMT-B also
has a considerable executive function component. Deﬁcits in
attention, working memory, and speed of processing were
detected in patients with HF in most studies [11–13, 42–
47, 50, 52, 56, 61–64]b u tn o ta l l[ 44, 47, 48, 54, 65]. Given
that these domains are mainly aﬀected in vascular dementia
it is possible that CI in HF and vascular dementia may share
similar pathophysiologic mechanisms [66].
4.3. Executive Functions. Executive functioning refers to the
cognitive abilities needed for daily life. Under this term, a
wide range of cognitive processes and behavioral competen-
ciesareincluded,someofthembeingverbalreasoning,prob-
lem solving, planning, multitasking, cognitive ﬂexibility and
the ability to deal with novelty [67]. These skills primarily
involve the frontal and prefrontal cortex. Complex cortical
and subcorticalcircuits werealsorecognized to participate in
executivefunctioning[68].Deﬁcitsinexecutivefunctionsare
associated with a decline in one’s ability to fulﬁll the require-
ments of everyday life. These deﬁcits are common and occur
early in the course of frontotemporal and vascular demen-
tia. A number of tests are available for evaluating executive
functions. The Stroop Test, the TMT-B, the letter ﬂuency test
andtheWisconsinCardSortingTest(WCST)arecommonly,
used tests in clinical studies [69]. In patients with HF, the
majority of studies found signiﬁcant impairment in mea-
sures of executive functioning [11, 43, 44, 49, 51, 52, 61, 64],
whereas two studies did not conﬁrm such deﬁcits [13, 20].
4.4. Language. Language deﬁcits are quite common in
dementias. Patients usually complain of diﬃculties in word
ﬁnding and naming. They may use related words instead of
the target word, have trouble following instructions or stay-
ing on a conversation. Patients also have impairment in
word recognition in reading and writing [70]. The main
brain regions for language are Broca’s area, which is related
to motor aspects of speech and Wernicke’s area, which is
responsible for language perception. These two regions are
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parietal regions, forming a complex network involved in
language function. Evaluation of language domain includes
assessment of naming, repetition, following commands,
verbal ﬂuency, reading and writing. Boston Naming Test
(BNT), Benton Controlled Oral Word Association Test
(COWAT), Token Test, and semantic ﬂuency task are some
useful neuropsychological tests for examination of language
function. It should be noted that language disturbance can
interfere with the patient’s performance in other cognitive
domains. Compared to other domains, there has been little
work on language deﬁcits in patients with HF. Two studies
reported impaired performance on language measures in
patients with HF [20, 52].
4.5.VisuospatialFunction. Visuospatialfunctionreferstothe
visual perception of the environment and the spatial rela-
tionships between the objects. Common manifestations of
visuospatial deﬁcits include impairment in navigation and
topographical orientation and diﬃculty in dressing, recog-
nizing familiar faces, or grasping objects [71]. The neural
network that mediates visuospatial cognition is widely
distributed and includes areas of parietal lobes, occipital
cortex,lateralprefrontalcortex,medialandinferiortemporal
cortex, basal ganglia, and white-matter tracts. Neuropsy-
chological tests for the assessment of visuospatial functions
include Benton Facial Recognition Test (FRT), Judgement
of Line Orientation Test (JLO), and Block Design Test. The
Clock Drawing Test (CDT) is also widely used for evalua-
tion of visuospatial and constructional ability. Deﬁcits in
visuospatial perception and construction are a prominent
manifestation of Alzheimer’s disease. In patients with HF
some studies noticed visuoperceptual deﬁcits [47, 49, 53].
Another study, however, did not replicate this ﬁnding [52].
Given the high occurrence of deﬁcits in cognitive func-
tion in patients with HF and their prognostic value in the
course of HF, adequate assessment and early detection of
CI is essential. HF patients with CI may have diverse pat-
terns of cognitive domain involvement which can be under-
stood considering the pathophysiology of CI in HF where a
concomitantanduneveninvolvementofmultiplebrainareas
occurs.Allthesecognitivedomainsshouldbeincludedinthe
assessment of CI in HF in order to achieve both reliability
and sensitivity.
Most studies have used various measures of cognitive
functioning, and currently there is no consensus among
investigators regarding the optimum neuropsychological
tests to assess patients with HF. Brief screening instruments
such as the MMSE or the Montreal Cognitive Assessment
(MoCA) can be easily administered by health professionals
in the outpatient clinical practice to conﬁrm the presence
of cognitive impairment. Brief tests, however, may be insuf-
ﬁcient in identifying subtle cognitive deﬁcits and more
detailed neuropsychological assessment will be required. On
the other hand, implementation of comprehensive series of
tests requires speciﬁc training for administration and inter-
pretation, is time consuming, and consequently may aﬀect
performance and compliance of participants. Future studies
therefore should focus on validating a screening instrument
that combines brevity, ease of use, and sensitivity to detect
in HF patients the presence of cognitive impairment in each
speciﬁc domain.
5. Severity Progression of CI
The prevalence of CI severity in HF patients with CI has
not been adequately addressed in the literature. In addition,
no standard criteria were used for delineating between mild,
moderate, and severe CI in the studies. Most of the patients
withHFandCIinthesestudieshadmildimpairmentincog-
nition, whereas about 25% had moderate-to-severe CI [9,
56, 72]. Furthermore, the degree of cognitive decline in HF
patients appears to correlate with the severity of HF. Zuccal` a
et al. [23] in a study of 57 patients with HF described
a nonlinear relationship between left ventricular ejection
fraction and MMSE scores. Interestingly, a greater decrease
in rate of MMSE scores was revealed for ejection fraction
(EF) values <30%. A similar relationship between measures
of verbal memory and EF drop below 30% was noted by
another group in patients older than 63 years [73]. Likewise,
other studies found that decrease in cardiac output [21, 25],
long duration of HF [74], and higher New York Heart Asso-
ciation (NYHA) class of the disease [75] parallel the severity
of cognitive impairment.
Another important issue which has received much atten-
tion lately is whether cognitive impairment in patients with
HF progresses to dementia over time, remains stable, or even
remit. In an important population-based cohort study [27]
Qiu et al. investigated the progression to dementia of 205
individuals with HF over a 9-year follow-up period. At base-
line assessment HF patients, although nondemented, had
lower cognitive performance measured by MMSE test com-
paredtocontrols.Thesepatients,inthelong-termfollow-up,
were at increased risk of progression to dementia (HR: 1.84,
C.I.: 1.35–2.51) or Alzheimer’s disease (HR: 1.80, C.I.: 1.25–
2.61). Interestingly, the use of antihypertensive drugs seemed
to counteract the eﬀect of HF on dementia risk. Another
study in patients aged >80 years examined the relationship
between HF and the change over time of speciﬁc cognitive
domains. It was shown that measures of episodic memory
decline more in HF patients compared to the group without
HF [47].
Finally,somestudiesreportedimprovementsincognitive
performance of HF patients over time which could be attri-
buted to improvement of cerebral hypoperfusion and con-
sequently neuronal function due to optimum management
of heart failure [76, 77], initiation of ACE inhibitors [14], or
implementation of exercise training programs [64].
6. Impact of CI in HF
Deﬁcits in attention, learning, memory, executive functions,
and psychomotor speed observed in high prevalence in
patients with HF may impair their ability to carry out self-
careandadheretotreatmentrequirements.Suchdeﬁcitsmay
also compromise patients’ capacity to recognize HF worsen-
ing symptoms and make appropriate decisions about their
health care [8]. In a recent study [78] mild CI was a signiﬁ-
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self-conﬁdence scores with other determinants of self-
care being severity of HF and presence of comorbidities. In
addition, HF patients with CI had greater diﬃculty with
medication management [79], were less likely to participate
in outpatient treatment programs [74], and failed to recog-
nize early symptoms and make the appropriate self-care
decisions [80, 81]. As a result, these patients were at
increased risk of HF decompensation, unplanned hospital
admissions or even death [82]. These data suggest that CI
may ultimately represent a risk factor of suboptimal health
care and worse outcome of HF patients. Impairments in
attention, judgment, and speed of information processing
should be taken into account when treatment strategies are
planned.
A number of studies in patients with HF also examined
the impact of CI on disability in daily activities, mortality,
and quality of life. The functional independence in daily
activities was investigated in a large multicentre study in
patients with HF. The study revealed that CI was associated
withasixfoldincreaseinfunctionaldisability(OR:6.49;95%
C.I.: 4.39–9.59) independently of any potential confounders
such as age, sex, comorbidities, medications or low blood
pressure [83]. Dependence and increased disability are
known predictors of raised mortality and increased hospital
readmission rates. CI was also associated with increased risk
ofmortality.Inastudyinvestigatingthein-hospitalmortality
among HF patients, CI was found to increase the mortality
by ﬁve times (Relative Risk (RR): 4.9; 95% C.I.: 2.9–8.3) after
adjusting for multiple confounders [84]. CI, therefore, seems
to represent a hidden comorbidity with an adverse impact
on disease course, inﬂuencing the burden of disease, survival
rates, and resource consumption. Finally, cognitive decline
that accompanies HF may negatively aﬀect many aspects of
daily life and the patients’ perceptions of quality of life and
well-being. In a recent study [85], signiﬁcant determinants
of the patients’ quality of life included disease severity, age,
depressive symptoms, and memory measures although the
latter accounted only for a small amount of the observed
variance.
7. Therapeutic Implications
A small number of studies have addressed the inﬂuence of
HF treatment on cognitive performance of patients with HF.
In a retrospective database analysis of 1220 patients with HF,
the use of ACE inhibitors was associated with improvement
in cognitive performance (OR: 1.57; 95% C.I.: 1.18–2.08).
Furthermore, the probability of improvement increased with
higher dosages of ACE inhibitors and longer duration of
treatment [14]. In addition, the same group of investigators
reported [86] that the use of digoxin also improved cognitive
performance among older patients with HF, reaching an
OR of 1.69 (95% CI: 1.20–2.38). In another study of 50
patients with severe HF that were reassessed 6 weeks after the
introduction of the appropriate medications, it was shown
that eﬀective treatment of HF patients according to their
needs with diuretics, ACE inhibitors, cardiotonic medication
(such as digoxin), and antiarrhythmic drugs had beneﬁcial
eﬀects in patients’ cognitive performance and in particular
in attentional and visuospatial scores [87]. These studies
provided valuable evidence that speciﬁc medications used in
HF such as ACE inhibitors and digoxin as well as optimal HF
therapy may have beneﬁcial eﬀects on cognitive performance
of HF patients. However, further research is needed mainly
from randomized trials in order to conﬁrm these results and
establish possible favorable role of various medications on
cognition.
Somestudiesalsoexaminedtheroleofnonpharmacolog-
ical approaches on cognition in patients with HF. In agree-
ment with pharmacological treatments invasive methods
were also demonstrated to improve cognition. It was report-
ed that impaired cognitive function in patients with HF was
signiﬁcantly improved after heart transplantation [42, 65].
Ofnote,pacemakerimplantationinbradycardicpatientswas
associated with improvement in verbal cognitive function
[88]. Two studies tested the impact physical activity on
cognitive function of HF patients. As expected, physical acti-
vity was demonstrated to have beneﬁcial eﬀects on cognitive
performance [64, 89]. Finally, the eﬃcacy of cognitive train-
ing intervention known as cognitive rehabilitation on mental
performance was evaluated in patients with HF. The authors
through structured cognitive training programs designed
to improve several aspects of cognition found signiﬁcant
improvements on measures of working memory, psycho-
motor speed, executive function, and memory [90]. These
interesting results should be further investigated especially in
larger randomized controlled trials.
There are no current studies examining the eﬀects of the
acetylcholinesteraseinhibitors(i.e.,thegroupofmedications
licensed for the symptomatic treatment of Alzheimer’s dis-
ease) on cognitive performance of patients with HF. Given
that acetylcholinesterase inhibitors were also found eﬃca-
ciousinvasculardementia,asimilareﬀectmightbeexpected
inpatientswithHF.Otherapproachessuchasrepetitivetran-
scranial magnetic stimulation [91] could also be considered
for CI in HF.
In summary, optimal HF treatment through pharmaco-
logical or invasive approaches ameliorates cognition among
patients with HF. Eﬀective control of vascular risk factors
should also be achieved considering the pathophysiology of
CIinHF.Patientsshouldbeencouragedtoparticipateincog-
nitive, physical, and social activities in order to improve their
cognitive performance.
8. Conclusions
Cognitive impairment is particularly common in HF and is
increasingly regarded as an independent prognostic factor of
HF outcome since it exerts signiﬁcant eﬀects on quality of
life, disability, morbidity, and mortality of patients with HF.
HF patients may present with deﬁcits in attention, learn-
ing ability and delay recall, working memory, executive
function, and psychomotor speed. They may have ﬂuctua-
tions in their cognition over time, depending on the eﬀective
management of HF, but they are at increased risk of progres-
sion to dementia. However, more conclusive evidence espe-
cially from prospective longitudinal studies is required for
the establishment of the long-term course of CI in HF6 Cardiology Research and Practice
patients and the possibility of emergence of modiﬁable risk
factors and new targets for intervention.
CI in HF seems to result from structural changes in
the brain cortex and white-matter due to microembolism,
chronic or intermittent cerebral hypoperfusion, and impair-
ed ﬂow regulation in small vessels which lead to cerebral
hypoxia and ischemic brain damage. Along with the neu-
rodegenerative component, there is also a functional and
consequently modiﬁable component of neuronal dysfunc-
tionduetodecreasedcerebralbloodﬂowwhichmayaccount
fortheimprovementsofcognitiveperformanceaftereﬀective
treatment of HF. Future studies are needed to provide fur-
ther insights into the relationship between CI and tissue
structural abnormalities and neuronal dysfunction.
Furthermore, a priority for researchers is the identiﬁ-
cation of a screening instrument sensitive to the cognitive
proﬁle of HF and easy to use in the clinical setting. With
increasing awareness that CI can worsen HF outcome, health
professionals should recognize the importance of early iden-
tiﬁcation and management of patients at risk of CI and
become familiar with assessment of cognitive performance
in their routine evaluations.
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